Clarity Pharmaceuticals Company Description

Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, engages in research and development of radiopharmaceuticals products for oncology in Australia and the United States.

The company’s lead product is SAR-bisPSMA, a theranostic radiopharmaceutical for the treatment of Prostate Specific Membrane Antigen (PSMA) cancer.

It also develops SAR-Bombesin, a pan cancer theranostic radiopharmaceutical to treat prostate, breast, ovarian, urinary, small cell lung cancer, as well as glioblastoma and gastrointestinal stromal tumours; and SARTATE, a theranostic radiopharmaceutical for the treatment of somatostatin receptor 2 (SSTR2) cancer.

The company was incorporated in 2010 and is based in Sydney, Australia.

Clarity Pharmaceuticals Ltd

Country	Australia
Founded	2010
Industry	Biotechnology
Sector	Healthcare
Employees	69
CEO	Michelle Parker

Contact Details

Address: National Innovation Centre Sydney, NSW 2015 Australia
Phone	61 2 9209 4037
Website	claritypharmaceuticals.com

Stock Details

Ticker Symbol	CU6
Exchange	Australian Securities Exchange
Fiscal Year	July - June
Reporting Currency	AUD
ISIN Number	AU0000165375
SIC Code	2834

Key Executives

Name	Position
Michelle Parker	Chief Executive Officer, MD and Executive Director
Dr. Alan John Taylor Ph.D.	Executive Chairman
David K. Green BEc., CA	Chief Financial Officer
Dr. Colin David Biggin Ph.D.	Chief Operating Officer and Non-Independent Executive Director
Dr. Ellen van Dam Ph.D.	Chief Scientific Officer
Lisa Sadetskaya	Director of Corporate Communications.
Mary Bennett	Head of People and Culture
Shaemus Gleason	Executive Vice President of Operations
Dr. Othon Gervasio	Chief Medical Officer
Eva Lengyelova	Executive Vice President of Clinical Development